reva medical inc - cdi (RVALL) Key Developments
REVA Medical, Inc. Releases Initial Clinical Results for Fantom Scaffold
May 21 15
REVA Medical, Inc. released initial clinical data on a subset of patients treated with the Fantom sirolimus-eluting bioresorbable scaffold at the Paris Course on Revascularization (EuroPCR). The FANTOM I pilot clinical trial, which enrolled patients with the Fantom scaffold at two clinical sites in Brazil and Poland, was designed to provide early clinical data on the device. In these patients acute performance was demonstrated with 100% technical and procedural success and no reported Major Adverse Cardiac Events (MACE) to date, with no incidence of ischemic target lesion revascularization (TLR), myocardial infarction (heart attack) or stent thrombosis. REVA is currently enrolling patients in the FANTOM II trial, which is designed to provide the necessary data for a European CE Mark application of Fantom.
Reva Medical, Inc. Expands FANTOM II Clinical Trial to Australia
May 15 15
REVA Medical, Inc. announced that the FANTOM II clinical trial is now enrolling patients with the Fantom sirolimus-eluting bioresorbable scaffold in Australia. This is in addition to previously announced sites in Brazil and Europe. The Fantom scaffold, made from REVA's advanced proprietary polymer, is designed to allow the restoration of blood flow in patients being treated for coronary artery disease, then resorb from the body over time. The FANTOM II trial is enrolling patients to support a European CE Mark application, which is expected to occur by mid-2016.
REVA Medical, Inc. - Shareholder/Analyst Call
May 15 15
2015 annual general meeting of stockholders
REVA Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 14 15
REVA Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company's loss from operations of $4,853,000 compared to $7,272,000 a year ago. Net loss and comprehensive loss was $23,357,000 compared to $7,276,000 a year ago. Net loss per share, basic and diluted was $0.70 compared to $0.22 a year ago. Net cash used for operating activities was $4,962,000 compared to $6,649,000 a year ago. Purchases of property and equipment were $281,000 compared to $216,000 a year ago.
REVA Medical, Inc. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015
Apr 30 15
REVA Medical, Inc. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the period, the company's net operating cash outflows was $4,961,000. Payment for acquisition of physical non-current assets was $282,000.